TER.NASDAQTeradyne, INC

Form 4: Teradyne Director Sells Shares Under 10b5-1 Plan

Sentiment:

Statement of Changes in Beneficial Ownership


Teradyne Director Mercedes Johnson reported a sale of 625 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • Director Mercedes Johnson sold 625 shares of Teradyne, Inc. common stock on April 6, 2026.
  • The sale was executed at a price of $312.20 per share.
  • Following the transaction, the reporting person directly beneficially owns 6,363 shares.
  • An additional 1,876 shares are held indirectly by The Mercedes Johnson Trust, where the reporting person is trustee and sole beneficiary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction executed under a pre-established trading plan, which is a common practice for compliance.

Negatives

  • Director Mercedes Johnson sold 625 shares of common stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a pre-planned sale, often used by executives and directors to diversify holdings or manage personal finances while adhering to insider trading regulations.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Rule 10b5-1 Plan AdoptionReporting Person adopted a sales plan intended to comply with Rule 10b5-1.02/03/2025Facilitates pre-planned stock sales by insiders, providing a defense against insider trading allegations.

Stakeholder Impact

  • Shareholders: The sale by a director may be perceived by some shareholders as a negative signal, although the use of a 10b5-1 plan mitigates concerns about insider knowledge.
  • Management: Demonstrates adherence to corporate governance and insider trading regulations.

Key Dates

DateDescription
02/03/2025Date the Rule 10b5-1 sales plan was adopted by the Reporting Person.
04/06/2026Date of the transaction (sale of common stock).
04/07/2026Date the Form 4 was signed by the attorney-in-fact.

Keywords

Teradyne, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Director Transaction, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.